BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37726177)

  • 1. Structural dynamics at the active site of the cancer-associated flavoenzyme NQO1 probed by chemical modification with PMSF.
    Grieco A; Ruiz-Fresneda MA; Gómez-Mulas A; Pacheco-García JL; Quereda-Moraleda I; Pey AL; Martin-Garcia JM
    FEBS Lett; 2023 Nov; 597(21):2687-2698. PubMed ID: 37726177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.
    Asher G; Dym O; Tsvetkov P; Adler J; Shaul Y
    Biochemistry; 2006 May; 45(20):6372-8. PubMed ID: 16700548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modular droplet injector for sample conservation providing new structural insight for the conformational heterogeneity in the disease-associated NQO1 enzyme.
    Doppler D; Sonker M; Egatz-Gomez A; Grieco A; Zaare S; Jernigan R; Meza-Aguilar JD; Rabbani MT; Manna A; Alvarez RC; Karpos K; Cruz Villarreal J; Nelson G; Yang JH; Carrion J; Morin K; Ketawala GK; Pey AL; Ruiz-Fresneda MA; Pacheco-Garcia JL; Hermoso JA; Nazari R; Sierra R; Hunter MS; Batyuk A; Kupitz CJ; Sublett RE; Lisova S; Mariani V; Boutet S; Fromme R; Grant TD; Botha S; Fromme P; Kirian RA; Martin-Garcia JM; Ros A
    Lab Chip; 2023 Jun; 23(13):3016-3033. PubMed ID: 37294576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.
    Winski SL; Faig M; Bianchet MA; Siegel D; Swann E; Fung K; Duncan MW; Moody CJ; Amzel LM; Ross D
    Biochemistry; 2001 Dec; 40(50):15135-42. PubMed ID: 11735396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H:quinone oxidoreductase 1 (NQO1).
    Lienhart WD; Strandback E; Gudipati V; Koch K; Binter A; Uhl MK; Rantasa DM; Bourgeois B; Madl T; Zangger K; Gruber K; Macheroux P
    FEBS J; 2017 Apr; 284(8):1233-1245. PubMed ID: 28236663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
    Kadela-Tomanek M; Bębenek E; Chrobak E; Marciniec K; Latocha M; Kuśmierz D; Jastrzębska M; Boryczka S
    Eur J Med Chem; 2019 Sep; 177():302-315. PubMed ID: 31158746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).
    Megarity CF; Abdel-Aal Bettley H; Caraher MC; Scott KA; Whitehead RC; Jowitt TA; Gutierrez A; Bryce RA; Nolan KA; Stratford IJ; Timson DJ
    Chembiochem; 2019 Nov; 20(22):2841-2849. PubMed ID: 31165578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
    Pey AL; Megarity CF; Timson DJ
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase(1.).
    Lienhart WD; Gudipati V; Uhl MK; Binter A; Pulido SA; Saf R; Zangger K; Gruber K; Macheroux P
    FEBS J; 2014 Oct; 281(20):4691-4704. PubMed ID: 25143260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural dynamics and functional cooperativity of human NQO1 by ambient temperature serial crystallography and simulations.
    Grieco A; Boneta S; Gavira JA; Pey AL; Basu S; Orlans J; Sanctis D; Medina M; Martin-Garcia JM
    Protein Sci; 2024 Apr; 33(4):e4957. PubMed ID: 38501509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases.
    Martinek V; Kubickova B; Arlt VM; Frei E; Schmeiser HH; Hudecek J; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():57-70. PubMed ID: 22167209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands.
    Medina-Carmona E; Palomino-Morales RJ; Fuchs JE; Padín-Gonzalez E; Mesa-Torres N; Salido E; Timson DJ; Pey AL
    Sci Rep; 2016 Feb; 6():20331. PubMed ID: 26838129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and genetic analysis of NAD(P)H:quinone oxidoreductase 1 (NQO1).
    Siegel D; Kepa JK; Ross D
    Curr Protoc Toxicol; 2007; Chapter 4():Unit4.22. PubMed ID: 23045144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.
    Hassani M; Cai W; Koelsch KH; Holley DC; Rose AS; Olang F; Lineswala JP; Holloway WG; Gerdes JM; Behforouz M; Beall HD
    J Med Chem; 2008 Jun; 51(11):3104-15. PubMed ID: 18457384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity-based small fluorescent probe for NAD(P)H:quinone oxidoreductase 1 (NQO1). Design, synthesis and pharmacological evaluation.
    Bian J; Li X; Xu L; Wang N; Qian X; You Q; Zhang X
    Eur J Med Chem; 2017 Feb; 127():828-839. PubMed ID: 27829520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems.
    Anwar A; Dehn D; Siegel D; Kepa JK; Tang LJ; Pietenpol JA; Ross D
    J Biol Chem; 2003 Mar; 278(12):10368-73. PubMed ID: 12529318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.
    Mendoza MF; Hollabaugh NM; Hettiarachchi SU; McCarley RL
    Biochemistry; 2012 Oct; 51(40):8014-26. PubMed ID: 22989153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
    Zhang K; Wang K; Zhang X; Qian Z; Zhang W; Zheng X; Wang J; Jiang Y; Zhang W; Lu Z; Hao H; Jiang S
    J Med Chem; 2022 Jun; 65(11):7746-7769. PubMed ID: 35640078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides.
    Kucera HR; Livingstone M; Moscoso CG; Gaikwad NW
    Free Radic Res; 2013 Dec; 47(12):1016-26. PubMed ID: 24074361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
    Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.